Q2 2025 Earnings Call Transcript August 6, 2025 Novavax, Inc. beats earnings expectations. Reported EPS is $0.601, ...

Novavax (NVAX) stock gains as the company beats Q2 revenue estimates and raises its 2025 revenue outlook, buoyed by ...

On Wednesday, Novavax Inc. (NASDAQ:NVAX) reported second-quarter 2025 sales of $239.24 million, compared to $415 million a year ago, beating the consensus of $156.29 million. The company completed the ...

Novavax posted a surprise profit in Q2 2025, reporting GAAP EPS of $0.62 compared to an expected loss of $0.04 per share. Revenue (GAAP) was $239 million, well above the analyst estimate of $152.61 ...

Novavax on Wednesday raised its full-year revenue forecast as it received a $175 million milestone payment from Sanofi ...

Novavax (NASDAQ:NVAX) was on track to end its seventh consecutive session in the red territory after shares of the company ...

Novavax (NVAX) closed the most recent trading day at $6.97, moving +1.9% from the previous trading session. The stock's change was more than the S&P 500's daily gain of 0.14%. On the other hand ...

Novavax (NVAX) closed the most recent trading day at $7.64, moving -2.55% from the previous trading session. This move lagged the S&P 500's daily gain of 0.07%. Meanwhile, the Dow experienced a drop ...

Novavax (NVAX) ended the recent trading session at $6.85, demonstrating a -2.28% change from the preceding day's closing price. This move lagged the S&P 500's daily loss of 0.13%. At the same time, ...

Shares of Novavax Inc. NVAX slid 2.28% to $6.85 Wednesday, on what proved to be an all-around mixed trading session for the ...

On June 17, Citi initiated coverage of Novavax Inc. (NASDAQ:NVAX) with a Sell rating and a $6 price target. A closeup of a vial of the biotechnology company’s vaccines.